Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vito Barbieri

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Journal for Immunotherapy of Cancer|June 20, 2020
Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockadePierpaolo Correale, Rita Emilena Saladino, Diana Giannarelli, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinomaAlice Baggi, Pietro Quaglino, Marco Rubatto, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2022
Corrigendum to "Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma" [Eur J Canc 157 (2021) 250-258]Alice Baggi, Pietro Quaglino, Marco Rubatto, et al.
Journal of Hematology & Oncology|June 26, 2023
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation studyPierfrancesco Tassone, Maria Teresa Di Martino, Mariamena Arbitrio, et al.
Translational Cancer Research|February 4, 2022
Listening understanding and acting (lung): focus on communicational issue in thoracic oncologyClaudia Yvonne Finocchiaro, Alessandra Rota, Vito Barbieri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2024
Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)Francesco Passiglia, Angela Listì, Paolo Bironzo, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Journal for Immunotherapy of Cancer|June 20, 2020
Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockadePierpaolo Correale, Rita Emilena Saladino, Diana Giannarelli, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinomaAlice Baggi, Pietro Quaglino, Marco Rubatto, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2022
Corrigendum to "Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma" [Eur J Canc 157 (2021) 250-258]Alice Baggi, Pietro Quaglino, Marco Rubatto, et al.
Journal of Hematology & Oncology|June 26, 2023
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation studyPierfrancesco Tassone, Maria Teresa Di Martino, Mariamena Arbitrio, et al.
Translational Cancer Research|February 4, 2022
Listening understanding and acting (lung): focus on communicational issue in thoracic oncologyClaudia Yvonne Finocchiaro, Alessandra Rota, Vito Barbieri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2024
Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)Francesco Passiglia, Angela Listì, Paolo Bironzo, et al.
Pageof 5